EGFR and non-small cell lung carcinoma: Objective response rate (ORR) was 70.6% (12/17) in EGFR-mutant NSCLC patients treated with bevacizumab plus chemotherapy and 50.0% (5/10) in those with chemotherapy alone (P = 0.415) (Table 2).